Supreme Court Shouldn't Hear Tamoxifen Cases: SG
The U.S. Supreme Court should not use the Tamoxifen Citrate antitrust lawsuits as an opportunity to weigh in on the issue of authorized generics, even though the appeals court that decided...To view the full article, register now.
Already a subscriber? Click here to view full article